These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28061552)

  • 61. Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia.
    Giljević JS; Rajačić N; Mikulić D; Batoš AT
    Children (Basel); 2022 Jun; 9(7):. PubMed ID: 35883927
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cost-effectiveness analysis of dinutuximab β for the treatment of high-risk neuroblastoma in China.
    Shen AL; Zhao J; Yu LT; Zhang AA; Wu B; Fang Y; Han YL; Li CS; Li ZL; Gao YJ; Zhang SG
    Pediatr Blood Cancer; 2023 Dec; 70(12):e30680. PubMed ID: 37715719
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ethical issues for control-arm patients after revelation of benefits of experimental therapy: a framework modeled in neuroblastoma.
    Unguru Y; Joffe S; Fernandez CV; Yu AL
    J Clin Oncol; 2013 Feb; 31(5):641-6. PubMed ID: 23295797
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy.
    Nassin ML; Nicolaou E; Gurbuxani S; Cohn SL; Cunningham JM; LaBelle JL
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):452-459. PubMed ID: 29191664
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
    Lode HN; Xiang R; Varki NM; Dolman CS; Gillies SD; Reisfeld RA
    J Natl Cancer Inst; 1997 Nov; 89(21):1586-94. PubMed ID: 9362156
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of
    Pilgrim AA; Jonus HC; Ho A; Cole AC; Shim J; Goldsmith KC
    Oncoimmunology; 2023; 12(1):2240678. PubMed ID: 37554309
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.
    Siebert N; Seidel D; Eger C; Brackrock D; Reker D; Schmidt M; Lode HN
    J Immunol Methods; 2013 Dec; 398-399():51-9. PubMed ID: 24055592
    [TBL] [Abstract][Full Text] [Related]  

  • 68. In brief: Dinutuximab (Unituxin) for high-risk neuroblastoma.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):e48. PubMed ID: 27027692
    [No Abstract]   [Full Text] [Related]  

  • 69. Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma.
    Anghelescu DL; Goldberg JL; Faughnan LG; Wu J; Mao S; Furman WL; Santana VM; Navid F
    Pediatr Blood Cancer; 2015 Feb; 62(2):224-228. PubMed ID: 25382742
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Local Sustained Dinutuximab Delivery and Release From Methacrylated Chondroitin Sulfate.
    Mistretta KS; Tiche J; Chiu B; Coburn JM
    J Biomed Mater Res A; 2024 Oct; ():. PubMed ID: 39359103
    [TBL] [Abstract][Full Text] [Related]  

  • 71. When Life Expectancy is Not Short Enough: A Perspective on the National Institute for Health and Care Excellence (NICE) Preliminary Guidance for Dinutuximab.
    Adamson PC; Park JR; Pearson AD
    Pediatr Blood Cancer; 2016 Jun; 63(6):962-3. PubMed ID: 26740172
    [No Abstract]   [Full Text] [Related]  

  • 72. Extensive small bowel pneumatosis and ischemia during dinutuximab therapy for high-risk neuroblastoma.
    Spencer K; Romberg E; Pinto N
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28147. PubMed ID: 31925911
    [No Abstract]   [Full Text] [Related]  

  • 73. Evidence for the efficacy of immunotherapy in children with high-risk neuroblastoma.
    Szychot E; Peregud-Pogorzelski J; Wawryków P; Brodkiewicz A
    Postepy Hig Med Dosw (Online); 2016 Sep; 70(0):1001-1004. PubMed ID: 27708204
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Disialoganglioside directed immunotherapy of neuroblastoma.
    Modak S; Cheung NK
    Cancer Invest; 2007 Feb; 25(1):67-77. PubMed ID: 17364560
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction.
    Cupit-Link M; Federico SM
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760578
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy.
    Simon T; Hero B; Faldum A; Handgretinger R; Schrappe M; Niethammer D; Berthold F
    Klin Padiatr; 2005; 217(3):147-52. PubMed ID: 15858706
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.
    Yu AL; Uttenreuther-Fischer MM; Huang CS; Tsui CC; Gillies SD; Reisfeld RA; Kung FH
    J Clin Oncol; 1998 Jun; 16(6):2169-80. PubMed ID: 9626218
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.
    Monterrubio C; Paco S; Olaciregui NG; Pascual-Pasto G; Vila-Ubach M; Cuadrado-Vilanova M; Ferrandiz MM; Castillo-Ecija H; Glisoni R; Kuplennik N; Jungbluth A; de Torres C; Lavarino C; Cheung NKV; Mora J; Sosnik A; Carcaboso AM
    J Control Release; 2017 Jun; 255():108-119. PubMed ID: 28412222
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Monitoring Immune Responses in Neuroblastoma Patients during Therapy.
    Szanto CL; Cornel AM; Vijver SV; Nierkens S
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32102342
    [TBL] [Abstract][Full Text] [Related]  

  • 80. State of the art in immunotherapy of neuroblastoma.
    Jabbari P; Hanaei S; Rezaei N
    Immunotherapy; 2019 Jun; 11(9):831-850. PubMed ID: 31094257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.